Next Article in Journal
High-Resolution Imaging Methods for Identification of Calcium Crystal Types in Osteoarthritis
Previous Article in Journal
Year in Review: Gout Clinical Research
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
GUCDD
Volume 1
Issue 1
10.3390/gucdd1010006
gucdd-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Metabolomics in Hyperuricemia and Gout

by
Rui Li
1,2,†,
Ningning Liang
2,3,†,
Yongzhen Tao
2 and
Huiyong Yin
1,2,3,4,5,*
1
School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
2
CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (CAS), Shanghai 200031, China
3
University of Chinese Academy of Sciences, CAS, Beijing 100049, China
4
Innovation Center for Intervention of Chronic Disease and Promotion of Health, Shanghai 200025, China
5
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR 999077, China
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this study.
Gout Urate Cryst. Depos. Dis. 2023, 1(1), 49-61; https://doi.org/10.3390/gucdd1010006
Submission received: 5 December 2022 / Revised: 16 March 2023 / Accepted: 17 March 2023 / Published: 21 March 2023
Browse Figures
Review Reports Versions Notes

Abstract

Urate is one of the key metabolites of purine metabolism, and the overproduction of urate in the liver or decreased excretion in the kidney in humans may lead to elevated levels of urate in the circulation, termed hyperuricemia (HU). The formation of monosodium urate (MSU) crystals in the joint or surrounding tissues may trigger inflammatory responses and gout attacks, which is the most common inflammatory arthritis. In addition to gout, HU has also been associated with many other metabolic diseases, such as cardiovascular disease, obesity, diabetes, fatty liver diseases, kidney diseases, hypertension, and various cancers. Overwhelming evidence indicates that HU and gout lead to systematic metabolic alterations underlying these metabolic disorders. As one of the most powerful omics techniques, metabolomics systematically analyzes all small-molecule metabolites in a biological system that directly reflect the physiological and pathological conditions. In recent years, metabolomics has been increasingly employed in clinical and experimental research in HU and gout. Emerging studies have developed predictive models to differentiate HU from gout based on metabolomics and machine-learning algorithms. In this review, we systematically summarize recent advances in metabolomic research in gout and HU in animal and human clinical studies. A comprehensive understanding of systemic metabolic changes caused by HU and gout may provide unprecedented insights into the pathological mechanisms in HU, gout, and related metabolic diseases, which may have a profound impact on the prevention, diagnosis, and treatment of HU and gout.

1. Introduction

Gout is a common chronic inflammatory disease of the joint caused by the deposition of monosodium urate crystals (MSU) [1,2]. Epidemiological data show that the incidence of gout varies widely from <1% to 6.8% around the world [3]. Clinical evidence suggests that persistent hyperuricemia (HU) is a prerequisite for gout [4], which is diagnosed as fasting blood urate levels over 420 μmol/L (7 mg/dL) in two separate days [5]. The increase of serum urate concentrations, HU, may be caused by multiple factors, such as upregulation of purine metabolism in the liver, increased dietary intake of purine, and/or impaired renal excretion. Gout flares are usually characterized by redness, swelling, heat, and pain in a single joint of the toes, ankles, and knee, and the inflammation resolves rapidly [6]. However, prolonged recurrent gout flares are often associated with the formation of tophi at the joint or extremity of the limb [7]. Urate lowering therapy (ULT) for HU or treatment of the inflammation by colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) is the key to clinical gout management [8]. Gout and HU are often associated with multiple metabolic co-morbidities, including hypertension, kidney diseases, cardiovascular disease, non-alcoholic fatty liver diseases, and various cancers [9,10].
Metabolomics is a relatively new omics technology that systematically identifies and quantifies all small-molecule metabolites in an organism [11,12]. As the substrates and products of biological activities, metabolites are essential for various cellular functions. Endogenous metabolites produced by the host organism and exogenous metabolites (xenobiotics) from microbiota, pharmaceuticals, or environmental chemicals constitute the entire metabolome, a collection of all metabolites. Emerging research has revealed that metabolites are not only the end products of biological processes, but also interact with the epigenome, transcriptome, and proteome [13,14,15,16]. For example, gout attacks triggered by MSU in the joints lead to systemic metabolic alterations. Previous studies found that MSU promotes GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages [17]. In addition, MSU regulates a unique JNK-dependent macrophage metabolic and inflammatory response [18]. In the progression of gout from HU, dynamic metabolic changes are often observed as a result of interplays among genetic factors, physiological status, and environmental insults. In this regard, traditional biochemical approaches focusing on a single or several metabolites to investigate such a complicated pathogenesis process in gout or HU may be inadequate. Thus metabolomic alterations could directly or indirectly reflect physiological and pathological states [19]. Therefore, metabolomics has become a powerful tool to investigate metabolic processes and identify disease-related biomarkers [20]. In recent years, innovative developments in analytic and bioinformatic technologies have greatly expanded the analytical capabilities of metabolomics to cover increasingly more metabolites at the systems biology level. Mass spectrometry (MS)-based analytical platforms provide powerful resolving capabilities for metabolomics [21], while bioinformatics tools provide deeper and broader insights for biological research [22,23].
The past decade has witnessed tremendous progress in understanding the pathophysiology of HU and gout, in which metabolomics plays an indispensable role (Figure 1). In this review, we summarize the advances of metabolomics studies on gout and HU. The challenges and future directions of metabolomics in this research area will also be discussed.

2. Analytical Technology for Metabolomics

The predominant analytical platforms used in metabolomics are nuclear magnetic resonance (NMR) spectroscopy or MS [24,25,26]. NMR provides an excellent tool for metabolite identification and quantification. The advantages of NMR are non-destructive analysis, a high reproducibility, and an unmatched structure-elucidation ability [27,28]. However, due to the limited sensitivity and absence of a proper separation system, NMR is currently overshadowed by MS in metabolomics analysis [25,29]. On the other hand, MS has been extensively used in metabolomics by being coupled with gas chromatography (GC) or liquid chromatography (LC) [12,19]. GC-MS is mainly used in the analysis of volatile (or volatile after derivatization) and thermally stable metabolites, whereas LC-MS is used to cover the majority of polar metabolites [30]. The columns used for LC separations can affect metabolomics analysis. For example, the LC columns based on hydrophilic interaction chromatography (HILIC) or C18 are widely used to separate aqueous metabolites, such as sugars [31,32], while the C8 column is good for the separation of less polar metabolites, such as free fatty acids [33,34]. Furthermore, the ionization mode, either in the positive or negative ion mode, may impact the coverage of metabolites as well. In general, basic metabolites are readily detected in the positive ion mode, whereas acidic compounds, such as fatty acids, are amenable for ionization in the negative ion mode. Thus, to improve the coverage of metabolomics analysis, both positive ionization and negative ionization are often performed, either in a separate acquisition or by switching between both modes within one method [31]. Furthermore, capillary electrophoresis (CE), ion mobility, and multidimensional LC provide supplementary separation techniques for LC-MS-based metabolomics [35,36]. Various mass analyzers, such as a quadrupole, ion trap, time of flight, Fourier transform ion cyclotron, and orbitrap, are used alone, in tandem or in combinations to trap, store, and resolve ions [37]. Given their high resolution, sensitivity, and throughput LC-MS-based approaches are capable of analyzing thousands of analytes simultaneously [21] and have therefore become the most popular techniques for metabolomics [38].
Multiple LC-MS strategies have been developed and routinely used for metabolomics. Dynamic multiple reaction monitoring (MRM)- and parallel reaction monitoring (PRM)-based targeted and pseudo-targeted metabolomics possess a high sensitivity and reliable quantitation accuracy but limited coverage [39,40]. Untargeted strategies, such as data-dependent acquisition (DDA) and data-independent acquisition (DIA), often based on high-resolution MS, have the best metabolite coverage but a compromised quantitation and reproducibility [41,42]. All the above approaches could perform a simultaneous qualification and quantitation of multiple metabolites in the biological matrix, but none of them are yet capable of covering entire metabolites. Thus, a combination of untargeted and targeted metabolomics approaches can provide a more comprehensive assessment of metabolites in a metabolome.

3. Metabolomics Data Analysis, Interpretation and Sharing

The diversity of metabolites, especially chemical structures with different regio- and stereoisomers, their natural abundance [43], and the different analytic approaches, as discussed above, present tremendous challenges to data analysis in metabolomics analysis. MS-based untargeted metabolomics data can be analyzed by a series of tools, such as xcms [44], MZmine [45], MS-DIAL [46], and skyline [47], to extract features of potential metabolite signals. To identify the features of metabolites, mass spectral databases are often used, such as the Human Metabolome Database (HMDB) [22], MassBank [48], GNPS [49], LipidBlast [50], and METLIN [51]. Traditional metabolite identification based on the exact mass, retention time, and MS/MS spectra similarity could appropriately annotate 12% of the total detected features in metabolomics analysis [52]. Molecular network-based metabolite identification methods are newly developed to maximize metabolite identification, such as MetDNA [53], GNPS [52], and NetID [54].
Once metabolites are identified and quantified, metabolomics-based statistical analysis is often performed to uncover specific biological activities associated with metabolomic alterations. Differential metabolites of statistical significance are then discovered by traditional statistical hypothesis testing or recently developed machine-learning models to link certain metabolic alterations to phenotypic changes [13,55]. Bioinformatics-based analysis tools and databases are utilized to interpret large-scale and high-dimensional complex metabolomics data into a set of biological phenomena for biologists to understand, such as MetaboAnalyst [56], Kyoto Encyclopedia of Genes and Genomes (KEGG) [57], Small Molecule Pathway Database (SMPDB) [58] and HMDB [22]. Bioinformatics-driven metabolic pathway analysis no longer considers only a single or a limited number of metabolite changes, but rather the systematic disturbance of global metabolism [13]. This trend is reflected in the development of methodology from overrepresentation analysis (ORA) and quantitative enrichment analysis (QEA) [59] to network-based metabolomic pathway analysis [56,60]. Metabolomics analysis combined with other omics, such as genomics, transcriptomics, and proteomics, has attracted widespread research interest. Several multi-omics databases are available to enable the analysis of broader interactions and the correlation of metabolites with genes and proteins, such as Reactome [61] and Recon3D [62].
Big data analysis has been demonstrated to be efficient in biological and clinical research in other well-established omics techniques [63] and is currently under development in metabolomics [13]. Several insightful initiatives [64,65] and guidelines [12] have been proposed to standardize metabolomics data acquisition and reporting. Metabolomics-specific data repositories, such as MetaboLights [23] and Metabolome Workbench [66], were recently established for metabolomics data deposition. These initiatives provide a way to conduct data sharing and re-analysis, but large-scale metabolomics data integration analyses across different platforms and laboratories are still limited and deserve future attention.

4. Metabolic Profiling and Metabolite Biomarker Discovery in Clinical Populations with HU and Gout

In large-scale clinical research, metabolomics is routinely applied to profile metabolic alterations in an attempt to uncover the pathological mechanisms and discover potential metabolite biomarkers [20]. Although HU is the major cause of gout, only a small fraction of HU patients experience gout flares, while a majority of patients (90%) remain asymptomatic. Currently, there is no reliable clinical approach for predicting HU patients who will develop gout. Metabolomics provides a novel tool to reveal metabolic alterations between HU and gout and has the potential to identify metabolite biomarkers for predicting the progression of HU to gout. In this regard, metabolomics has been performed in gout and HU patients to systematically profile their metabolic characterization compared to healthy controls (Table 1). Metabolites involved in amino-acid metabolism, lipid metabolism, purine metabolism, and energy metabolism have been discovered to be significantly different from healthy control in serum [31,67,68,69]. Other metabolic differences between HU and gout have been reported in recent metabolomics research, such as arginine biosynthesis, glycine, serine, and threonine metabolism, as well as some lipid metabolism [66,67]. Interestingly, some metabolites, such as those involved in tryptophan metabolism, neuroactive ligand-receptor interaction, and nitrogen metabolism pathway, were found to change at sequential gout progression stages [70], suggesting a role in the pathogenesis from HU to gout. The metabolomic observations in serum have been summarized in Figure 2 to provide a better overview of the altered pathways from controls to HU and gout. Similar alterations were observed in urine and fecal samples from gout patients [69,71,72]. Together, these global metabolomics profiles observed in metabolomics studies may reflect a pathological state and help to understand the underlying pathogenesis of HU and gout.
To discover potential metabolite biomarkers for gout, especially in asymptomatic HU cohorts with a high risk of gout, it is essential to include large clinical cohorts in metabolomics studies with proper statistical models. In recent research, up to 547 cases were included, and multiple machine-learning-based models were applied to select the most predictable biomarkers from untargeted metabolomics data [70,73]. Apart from the traditional gout indicator, urate, several novel biomarkers, such as pyroglutamic acid, glycocholate, lactic acid, glutamate, bilirubin, 2-methyl butyryl carnitine, isoxanthopterin, and kynurenic acid, were identified. Notably, some of these reports validated their selected biomarkers in separate validation cohorts [69,70,73,74] or by other absolute quantitative approaches [70,74,75], which show a better potential for translation into an early clinical diagnosis in gout.
Table 1. Metabolomic studies in human samples.
Table 1. Metabolomic studies in human samples.
DateSampleDiscovery Cohort Validation Cohort Technique PlatformUpregulated BiomarkersDownregulated BiomarkersConclusions
2021 [31]SerumGout (109) vs. healthy (119) LCMS Pyroglutamic acid, glycocholate, lactic acid, glutamateGlycine, serine, and threonine metabolism disorder
Arginine and proline metabolism disorder
Ascorbate and aldarate metabolism disorder
Alanine, aspartate, and glutamate metabolism disorder
Gout (109) vs. HU (102) Betaine, trigonelline, pipecolic acid,Glycocholate, uracil, myristic acid, arachidonateArginine biosynthesis↑
Glycine, serine, and threonine metabolism disorder
2018 [67]SerumGout (49) vs. healthy (50) NMRVLDL, isoleucine, leucine, glutamine, methionine, acetone, citrate, aspartate, creatinine, glucose, threonine, triglycerides, unsaturated lipids and phenylalanine Aminoacyl-tRNA biosynthesis↓
Valine, leucine and isoleucine biosynthesis↑
Nitrogen metabolism↑
Alanine, aspartate and glutamate metabolism↑
D-glutamine and D-glutamate metabolism disorder
Gout (49) vs. HU (50) VLDL, lipid, acetone, citrate, aspartate, glucose
2020 [68]SerumGout (31) vs. healthy (31) LCMS4-hydroxytriazolam, bilirubin, urate, 4E,15Z-Bilirubin IXa, androsterone sulfate, 5a-dihydrotestosterone sulfate, etiocholanolone sulfate, epiandrosterone sulfate, 1,2-Di-O-(8-hexadecenoyl)-3-O-(6-sulfoquinovopyranosyl)glycerol, PE(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) Primary bile acid biosynthesis↓
Purine metabolism↑
Glycerophospholipid metabolism disorder
2020 [69]Serum and UrineGout (30) vs. healthy (30)Gout (50) vs. healthy (50)LCMSPyroglutamic acid, Phe-Phe, 2-methylbutyryl carnitine Purine metabolism disorder
Branched-chain amino acids (BCAAs) metabolism disorder
Tricarboxylic acid cycle disorder
Synthesis and degradation of ketone bodies disorder
Bile secretion disorder
Arachidonic acid metabolism disorder
2018 [71]UrineGout (35) vs. healthy (29) GCMSUrate, isoxanthopterin Purine nucleotide synthesis↑
Amino acid metabolism↓
Purine metabolism↑
Lipid and carbohydrate metabolism disorder
2017 [72]FecesGout (26) vs. healthy (26) NMRAlanine, glycine, taurine, succinate, acetate, a-glucose, b-glucose, a-xylose Valine, asparagine, aspartate, citrulline, phenylalanine, a-ketoisocaproateUrate excretion disorder
Purine metabolism disorder
Inflammatory responses disorder
2021 [73]SerumGout (50) vs. HU (50)Gout (69) vs. HU (50)LCMS TAG 18:1-20:0-22:1, TAG 14:0-16:0-16:1Lipid disorders
2022 [75]SerumHU (20) vs. healthy (20) LCMS untargeted + targetedLactic acid, valine, palmitic acid, Tyrosine, phenylalanine, arachidonic acid, stearic acid, linoleic acid, oleic acid, lipids, LysoPC(18:0), LysoPC(16:0), LysoPC(18:1(9Z))Glycerophospholipid metabolism disorder
Arachidonic acid metabolism disorder
Sphingolipid metabolism disorder
Linoleic acid metabolism disorder
α-linolenic acid metabolism disorder
Phenylalanine, tyrosine, and tryptophan biosynthesis disorder
Phenylalanine metabolism disorder
2017 [74]SalivaGout (8) vs. healthy (15)Gout (30) vs. healthy (30)CICMS + assay kitsUrate, oxalic acid, L-homocysteic acid (HCA)
Gout (8) vs.
HU (15)		Gout (30) vs. HU (30)Urate, oxalic acid, L-homocysteic acid (HCA)
2022 [70]Serum5 sequential stages (347)5 sequential stages (200)LCMS untargeted + targetedkynurenic acid (KYNA), 5-hydroxyindole acetic acid (5-HIAA), DL-2-Aminoadipic acid (2AMIA)N1-Methyl-2-pyridone-5-carboxamide (2PY)KYNA and 5-HIAA are related to acute inflammation of gouty arthritis
2PY and 2AMIA are related to renal function damage caused by long-term HU

5. Multi-Omics and Big Data

The combination of metabolomics and other omics could provide comprehensive and novel insights into clinical and experimental research. Genotype-dependent metabolic phenotypes, such as urate and SLC2A9, 10-nonadecenoate (19:1n9)/10-undecenoate (11:1n1) and CYP4A, are discovered by analysis of GWAS with untargeted metabolomics [76,77]. There is a lack of aldehyde dehydrogenase 16A1 (ALDH16A1), which was discovered to be associated with serum urate levels and gout in humans [78] by potential interactions with hypoxanthine phosphoribosyltransferase 1 (HPRT1) [79]. In mice kidneys, significant changes in the transcriptional levels of cellular lipid metabolic genes and urate transporters as well as lipid profiles were consistent with metabolomics data [80], suggesting a potential role of ALDH16A1 and lipid metabolism in gout. Emerging data suggest that gut microbiota participate in purine and urate metabolism [81], crosstalk with the host immune system [82], and affect intestinal urate excretion [83,84]. Thus, in feces from gout patients, a combination of microbiome and metabolome analyses revealed an up-regulation of microbiota, such as Bacteroides, Porphyromonadaceae Rhodococcus, Erysipelatoclostridium and Anaerolineaceae, as well as altered metabolites involved in urate excretion, purine metabolism, and inflammatory responses [72]. A prospective cohort analysis of 105,703 UK Biobank (UKB) participants by targeted NMR metabolomics identified glycoprotein acetylation as a biomarker positively associated with the risk of incident gout and validated in 4804 non-overlapping participants [85].

6. Metabolomics in Experiment Models

Various animal models have been established for gout and HU research [86], and some of them have been used for metabolic studies. We summarized metabolomics studies in rodent models in Table 2.
Recently, an MSU crystal-induced gouty arthritis (GA) rat model was established by injecting an MSU crystals suspension (20 mg/mL) in the dorsal side of the right ankle. In this model, rat serum metabolomics profiling found that arachidonic acid, sphingolipid, and glycerophospholipid metabolism were significantly changed [87]. Consistently, in studies based on high fructose combined with a potassium-oxonate (HFCPO)-induced HU rat model, researchers used untargeted plasma metabolomics to find significant alterations between the HU group and control group. The differential metabolites included acylcarnitine and amino-acid-related metabolites [88]. In addition, urine samples have been widely used in metabolomics studies. In potassium-oxonate-induced HU rats, researchers used 1H NMR and LC-MS to conduct nontargeted metabolomics studies in plasma and urine samples. They discovered 21 metabolites in plasma and urine to be closely related to HU, such as pyruvate, lactate, creatine, glycine, lysophosphatidylcholine (LysoPC), and phosphatidylcholine (PC) [89]. LC-MS using multiple reaction monitoring modes has been applied to detect the macrophage metabolic changes in an acute gouty peritonitis mouse model after MSU stimulation. They found that IL-37 might alter the macrophage polarization status by metabolic reprogramming, primarily by reducing TCA and several amino acids and oligopeptides [90].
Medical treatments for HU and gout, such as ULT and anti-inflammatory therapies, may have a significant impact on systematic alterations in metabolism. A recent study using CE-TOFMS metabolomics tested the hypothesis that Xanthine oxidoreductase (XOR) inhibitors exert organ-protective effects [91]. The metabolomics focused on the renal metabolites in a rat model of renal I/R and found that XOR inhibitors can preserve tissue-specific concentrations of some high-energy phosphates, such as ATP and ADP.
Table 2. Metabolomic studies in rodent models of HU and gout.
Table 2. Metabolomic studies in rodent models of HU and gout.
DataAnalytical PlatformRodent ModelsDifferential Metabolites/
Metabolic Pathways
2022 [87]UPLC-QTOF-MS/MS MSU Crystal-Induced Gouty arthritis RatsArachidonic acid, sphingolipid, and glycerophospholipid metabolism
2021 [88]UPLC-QTOF/MSHigh fructose combined with potassium oxonate (HFCPO)-induced hyperuricemia RatsAcylcarnitine and amino acid related metabolites
2020 [89]1H NMR and UHPLC/Q-Orbitrap-MSPotassium oxonate induced hyperuricemia ratsPyruvate, lactate, creatine, glycine, LysoPC and PC and etc
2019 [91]Capillary electrophoresis–time-of-flight mass spectrometry (CE-TOFMS) Rat model of renal I/RPurine/pyrimidine metabolism
2022 [90]Shimadzu Nexera XR HPLC-MS SCIEX Triple Quad™ 3500 Acute gouty peritonitis mouse modelGlycolysis pathway

7. Summary and Future Directions

Gout and HU are closely associated with the dysregulation of multiple metabolic pathways. High-throughput omics techniques, such as metabolomics, have been increasingly recognized as indispensable tools to provide comprehensive insights at systems biology levels, which makes metabolomics a valuable tool for research on HU and gout. With a high coverage and large clinical cohorts, systematic metabolic alterations could be revealed. Thus, most of the metabolomics research in gout and HU focuses on profiling and discovering biomarkers in clinical studies. Some dysregulated metabolic pathways are found in the progression of gout, and multiple biomarkers are identified to differentiate different metabolic diseases. Recent years have witnessed the increasing integration of multi-omics studies in gout and related metabolic disorders. Particularly, some genetic variants are identified in GWAS studies, while gut microbiota and associated metabolites are also identified as risk factors for gout, which is deeply involved in metabolic alterations of the host. These findings have offered potential new strategies for the clinical prediction and treatment of gout. In clinical metabolomic studies, sample size, demographic characteristics and clinical parameters are key factors for identifying reproducible metabolites and pathways associated with metabolic diseases, including HU and gout. Furthermore, statistical analysis is important for omics analysis, covariates should be considered, and strict multiple hypothesis tests should be performed to minimize the risk of type 1 statistical errors.
Although tremendous progress has been made in recent years by applying metabolomics in gout and related research, the field still faces daunting challenges. First of all, the technology of metabolomics is still in its infancy. The coverage and repeatability of metabolomic studies remain unsatisfactory. On the other hand, standardized analytical methods and data-processing protocols have yet to be established, which hinders validation in clinical studies with different genetic, ethnic, and lifestyle backgrounds. Second, bioinformatics tools and databases for metabolomics are critical in data interpretation and mining. However, these tools for metabolomics remain underdeveloped compared with other relatively well-established omics techniques, such as genomics, transcriptomics, and proteomics, which makes them difficult to use in integrated omics studies. Third, the application of metabolomics in clinical gout research remains limited. More confirmatory studies should be performed in the future to validate metabolic profiling and biomarkers of gout with carefully designed clinical studies. Moreover, the development of bioinformatics tools and standardized protocols for sample collection, storage, preparation, quality control, and data reporting and sharing is instrumental in maximizing the power of metabolomics to understand the pathological mechanisms and developing metabolite biomarkers for HU, gout, and related metabolic diseases. Last but not least, multi-disciplinary efforts from basic sciences, clinicians, data processing, and policymakers are needed to ensure that the scientific findings in metabolomics benefit patients with HU and gout.

Author Contributions

Conceptualization, H.Y.; writing—original draft preparation, R.L. and N.L.; writing—review and editing, Y.T. and H.Y.; visualization, R.L. and N.L.; supervision, H.Y.; project administration, H.Y.; funding acquisition, H.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by grants from the National Key Research and Development Program of China (2022YFC2503300 and 2018YFA0800300) and National Natural Science Foundation of China (No. 32030053, 32150710522, and 32241017).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

N.L. and H.Y. are inventors of a pending Chinese patent for assessing risks of gout in hyperuricemia patients. SINH is actively seeking licensing opportunity for this patent.

References

  1. Dalbeth, N.; Gosling, A.L.; Gaffo, A.; Abhishek, A. Gout. Lancet 2021, 397, 1843–1855. [Google Scholar] [CrossRef]
  2. Desai, J.; Steiger, S.; Anders, H.-J. Molecular Pathophysiology of Gout. Trends Mol. Med. 2017, 23, 756–768. [Google Scholar] [CrossRef] [PubMed]
  3. Dehlin, M.; Jacobsson, L.; Roddy, E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat. Rev. Rheumatol. 2020, 16, 380–390. [Google Scholar] [CrossRef] [PubMed]
  4. Dalbeth, N.; Phipps-Green, A.; Frampton, C.; Neogi, T.; Taylor, W.J.; Merriman, T.R. Relationship between serum urate concentration and clinically evident incident gout: An individual participant data analysis. Ann. Rheum. Dis. 2018, 77, 1048–1052. [Google Scholar] [CrossRef] [PubMed]
  5. Fitzgerald, J.D.; Dalbeth, N.; Mikuls, T.; Brignardello-Petersen, R.; Guyatt, G.; Abeles, A.M.; Gelber, A.C.; Harrold, L.R.; Khanna, D.; King, C.; et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res. 2020, 72, 744–760. [Google Scholar] [CrossRef]
  6. Schumacher, H.R.; Taylor, W.; Edwards, L.; Grainger, R.; Schlesinger, N.; Dalbeth, N.; Sivera, F.; Singh, J.; Evans, R.; Waltrip, R.W.; et al. Outcome Domains for Studies of Acute and Chronic Gout. J. Rheumatol. 2009, 36, 2342–2345. [Google Scholar] [CrossRef]
  7. Hirsch, J.D.; Terkeltaub, R.; Khanna, D.; Singh, J.; Sarkin, A.; Shieh, M.; Kavanaugh, A.; Lee, S.J. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat. Outcome Meas. 2010, 1, 1–8. [Google Scholar] [CrossRef]
  8. Li, Q.; Li, X.; Wang, J.; Liu, H.; Kwong, J.S.; Chen, H.; Li, L.; Chung, S.C.; Shah, A.; Chen, Y.; et al. Diagnosis and treatment for hyperuricemia and gout: A systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019, 9, e026677. [Google Scholar] [CrossRef]
  9. Soltani, Z.; Rasheed, K.; Kapusta, D.R.; Reisin, E. Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal? Curr. Hypertens. Rep. 2013, 15, 175–181. [Google Scholar] [CrossRef]
  10. Puig, J.G.; Martínez, M.A. Hyperuricemia, gout and the metabolic syndrome. Curr. Opin. Rheumatol. 2008, 20, 187–191. [Google Scholar] [CrossRef]
  11. Perez De Souza, L.; Alseekh, S.; Scossa, F.; Fernie, A.R. Ultra-high-performance liquid chromatography high-resolution mass spectrometry variants for metabolomics research. Nat. Methods 2021, 18, 733–746. [Google Scholar] [CrossRef] [PubMed]
  12. Alseekh, S.; Aharoni, A.; Brotman, Y.; Contrepois, K.; D’Auria, J.; Ewald, J.; Ewald, J.C.; Fraser, P.D.; Giavalisco, P.; Hall, R.D.; et al. Mass spectrometry-based metabolomics: A guide for annotation, quantification and best reporting practices. Nat. Methods 2021, 18, 747–756. [Google Scholar] [CrossRef] [PubMed]
  13. Rinschen, M.M.; Ivanisevic, J.; Giera, M.; Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 2019, 20, 353–367. [Google Scholar] [CrossRef]
  14. Metallo, C.M.; Vander Heiden, M.G. Understanding metabolic regulation and its influence on cell physiology. Mol. Cell 2013, 49, 388–398. [Google Scholar] [CrossRef] [PubMed]
  15. Zhang, D.; Tang, Z.; Huang, H.; Zhou, G.; Cui, C.; Weng, Y.; Liu, W.; Kim, S.; Lee, S.; Perez-Neut, M.; et al. Metabolic regulation of gene expression by histone lactylation. Nature 2019, 574, 575–580. [Google Scholar] [CrossRef]
  16. Boon, R.; Silveira, G.G.; Mostoslavsky, R. Nuclear metabolism and the regulation of the epigenome. Nat. Metab. 2020, 2, 1190–1203. [Google Scholar] [CrossRef]
  17. Renaudin, F.; Orliaguet, L.; Castelli, F.; Fenaille, F.; Prignon, A.; Alzaid, F.; Combes, C.; Delvaux, A.; Adimy, Y.; Cohen-Solal, M.; et al. Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1beta activation on macrophages. Ann. Rheum. Dis. 2020, 79, 1506–1514. [Google Scholar] [CrossRef]
  18. Cobo, I.; Cheng, A.; Murillo-Saich, J.; Coras, R.; Torres, A.; Abe, Y.; Lana, A.J.; Schlachetzki, J.; Liu-Bryan, R.; Terkeltaub, R.; et al. Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response. Cell Rep. 2022, 38, 110489. [Google Scholar] [CrossRef]
  19. Newgard, C.B. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017, 25, 43–56. [Google Scholar] [CrossRef]
  20. Johnson, C.H.; Ivanisevic, J.; Siuzdak, G. Metabolomics: Beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 2016, 17, 451–459. [Google Scholar] [CrossRef]
  21. Alseekh, S.; Fernie, A.R. Metabolomics 20 years on: What have we learned and what hurdles remain? Plant J. 2018, 94, 933–942. [Google Scholar] [CrossRef] [PubMed]
  22. Wishart, D.S.; Guo, A.; Oler, E.; Wang, F.; Anjum, A.; Peters, H.; Dizon, R.; Sayeeda, Z.; Tian, S.; Lee, B.L.; et al. HMDB 5.0: The Human Metabolome Database for 2022. Nucleic Acids Res. 2022, 50, D622–D631. [Google Scholar] [CrossRef] [PubMed]
  23. Haug, K.; Cochrane, K.; Nainala, V.C.; Williams, M.; Chang, J.; Jayaseelan, K.V.; O’Donovan, C. MetaboLights: A resource evolving in response to the needs of its scientific community. Nucleic Acids Res. 2020, 48, D440–D444. [Google Scholar] [CrossRef]
  24. Shao, Y.; Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease. Mol. Neurodegener. 2019, 14, 3. [Google Scholar] [CrossRef] [PubMed]
  25. Lane, A.N.; Higashi, R.M.; Fan, T.W.M. NMR and MS-based Stable Isotope-Resolved Metabolomics and applications in cancer metabolism. TrAC Trends Anal. Chem. 2019, 120, 115322. [Google Scholar] [CrossRef]
  26. Griffin, J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 2003, 7, 648–654. [Google Scholar] [CrossRef]
  27. Vignoli, A.; Ghini, V.; Meoni, G.; Licari, C.; Takis, P.G.; Tenori, L.; Turano, P.; Luchinat, C. High-Throughput Metabolomics by 1D NMR. Angew. Chem. Int. Ed. 2019, 58, 968–994. [Google Scholar] [CrossRef]
  28. Takis, P.G.; Ghini, V.; Tenori, L.; Turano, P.; Luchinat, C. Uniqueness of the NMR approach to metabolomics. TrAC Trends Anal. Chem. 2019, 120, 115300. [Google Scholar] [CrossRef]
  29. Markley, J.L.; Brüschweiler, R.; Edison, A.S.; Eghbalnia, H.R.; Powers, R.; Raftery, D.; Wishart, D.S. The future of NMR-based metabolomics. Curr. Opin. Biotechnol. 2017, 43, 34–40. [Google Scholar] [CrossRef]
  30. Zhang, A.; Sun, H.; Wang, P.; Han, Y.; Wang, X. Modern analytical techniques in metabolomics analysis. Analyst 2012, 137, 293–300. [Google Scholar] [CrossRef]
  31. Shen, X.; Wang, C.; Liang, N.; Liu, Z.; Li, X.; Zhu, Z.J.; Merriman, T.R.; Dalbeth, N.; Terkeltaub, R.; Li, C.; et al. Serum metabolomics identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout. Arthritis Rheumatol. 2021, 73, 1738–1748. [Google Scholar] [CrossRef] [PubMed]
  32. Zhang, Z.; TeSlaa, T.; Xu, X.; Zeng, X.; Yang, L.; Xing, G.; Tesz, G.J.; Clasquin, M.F.; Rabinowitz, J.D. Serine catabolism generates liver NADPH and supports hepatic lipogenesis. Nat. Metab. 2021, 3, 1608–1620. [Google Scholar] [CrossRef] [PubMed]
  33. Hui, S.; Ghergurovich, J.M.; Morscher, R.J.; Jang, C.; Teng, X.; Lu, W.; Esparza, L.A.; Reya, T.; Le, Z.; Yanxiang Guo, J.; et al. Glucose feeds the TCA cycle via circulating lactate. Nature 2017, 551, 115–118. [Google Scholar] [CrossRef]
  34. Li, M.; He, X.; Guo, W.; Yu, H.; Zhang, S.; Wang, N.; Liu, G.; Sa, R.; Shen, X.; Jiang, Y.; et al. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. Nat. Cancer 2020, 1, 735–747. [Google Scholar] [CrossRef] [PubMed]
  35. Lv, W.; Shi, X.; Wang, S.; Xu, G. Multidimensional liquid chromatography-mass spectrometry for metabolomic and lipidomic analyses. TrAC Trends Anal. Chem. 2019, 120, 115302. [Google Scholar] [CrossRef]
  36. Zhou, Z.; Shen, X.; Chen, X.; Tu, J.; Xiong, X.; Zhu, Z.-J. LipidIMMS Analyzer: Integrating multi-dimensional information to support lipid identification in ion mobility—Mass spectrometry based lipidomics. Bioinformatics 2019, 35, 698–700. [Google Scholar] [CrossRef]
  37. Haag, A.M. Mass Analyzers and Mass Spectrometers. In Modern Proteomics—Sample Preparation, Analysis and Practical Applications; Springer International Publishing: Berlin/Heidelberg, Germany, 2016; pp. 157–169. [Google Scholar]
  38. Doerr, A. Global metabolomics. Nat. Methods 2017, 14, 32. [Google Scholar] [CrossRef]
  39. Zhou, J.; Yin, Y. Strategies for large-scale targeted metabolomics quantification by liquid chromatography-mass spectrometry. Analyst 2016, 141, 6362–6373. [Google Scholar] [CrossRef]
  40. Zheng, F.; Zhao, X.; Zeng, Z.; Wang, L.; Lv, W.; Wang, Q.; Xu, G. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography–mass spectrometry. Nat. Protoc. 2020, 15, 2519–2537. [Google Scholar] [CrossRef]
  41. Bonner, R.; Hopfgartner, G. SWATH data independent acquisition mass spectrometry for metabolomics. TrAC Trends Anal. Chem. 2019, 120, 115278. [Google Scholar] [CrossRef]
  42. Van Der Greef, J.; Van Wietmarschen, H.; Van Ommen, B.; Verheij, E. Looking back into the future: 30 years of metabolomics at TNO. Mass Spectrom. Rev. 2013, 32, 399–415. [Google Scholar] [CrossRef]
  43. Fernie, A.R.; Trethewey, R.N.; Krotzky, A.J.; Willmitzer, L. Metabolite profiling: From diagnostics to systems biology. Nat. Rev. Mol. Cell Biol. 2004, 5, 763–769. [Google Scholar] [CrossRef] [PubMed]
  44. Smith, C.A.; Want, E.J.; O’Maille, G.; Abagyan, R.; Siuzdak, G. XCMS:  Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification. Anal. Chem. 2006, 78, 779–787. [Google Scholar] [CrossRef] [PubMed]
  45. Pluskal, T.; Castillo, S.; Villar-Briones, A.; Orešič, M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinform. 2010, 11, 395. [Google Scholar] [CrossRef] [PubMed]
  46. Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.; Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat. Methods 2015, 12, 523–526. [Google Scholar] [CrossRef]
  47. Kirkwood, K.I.; Pratt, B.S.; Shulman, N.; Tamura, K.; Maccoss, M.J.; Maclean, B.X.; Baker, E.S. Utilizing Skyline to analyze lipidomics data containing liquid chromatography, ion mobility spectrometry and mass spectrometry dimensions. Nat. Protoc. 2022, 17, 2415–2430. [Google Scholar] [CrossRef]
  48. Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; et al. MassBank: A public repository for sharing mass spectral data for life sciences. J. Mass Spectrom. 2010, 45, 703–714. [Google Scholar] [CrossRef]
  49. Wang, M.; Carver, J.J.; Phelan, V.V.; Sanchez, L.M.; Garg, N.; Peng, Y.; Nguyen, D.D.; Watrous, J.; Kapono, C.A.; Luzzatto-Knaan, T.; et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat. Biotechnol. 2016, 34, 828–837. [Google Scholar] [CrossRef]
  50. Kind, T.; Liu, K.-H.; Lee, D.Y.; Defelice, B.; Meissen, J.K.; Fiehn, O. LipidBlast in silico tandem mass spectrometry database for lipid identification. Nat. Methods 2013, 10, 755–758. [Google Scholar] [CrossRef]
  51. Montenegro-Burke, J.R.; Guijas, C.; Siuzdak, G. METLIN: A Tandem Mass Spectral Library of Standards. In Computational Methods and Data Analysis for Metabolomics; Springer: New York, NY, USA, 2020; pp. 149–163. [Google Scholar] [CrossRef]
  52. Schmid, R.; Petras, D.; Nothias, L.-F.; Wang, M.; Aron, A.T.; Jagels, A.; Tsugawa, H.; Rainer, J.; Garcia-Aloy, M.; Dührkop, K.; et al. Ion identity molecular networking for mass spectrometry-based metabolomics in the GNPS environment. Nat. Commun. 2021, 12, 3832. [Google Scholar] [CrossRef]
  53. Shen, X.; Wang, R.; Xiong, X.; Yin, Y.; Cai, Y.; Ma, Z.; Liu, N.; Zhu, Z.-J. Metabolic reaction network-based recursive metabolite annotation for untargeted metabolomics. Nat. Commun. 2019, 10, 1516. [Google Scholar] [CrossRef] [PubMed]
  54. Chen, L.; Lu, W.; Wang, L.; Xing, X.; Chen, Z.; Teng, X.; Zeng, X.; Muscarella, A.D.; Shen, Y.; Cowan, A.; et al. Metabolite discovery through global annotation of untargeted metabolomics data. Nat. Methods 2021, 18, 1377–1385. [Google Scholar] [CrossRef] [PubMed]
  55. Sen, P.; Lamichhane, S.; Mathema, V.B.; McGlinchey, A.; Dickens, A.M.; Khoomrung, S.; Orešič, M. Deep learning meets metabolomics: A methodological perspective. Brief. Bioinform. 2021, 22, 1531–1542. [Google Scholar] [CrossRef] [PubMed]
  56. Pang, Z.; Zhou, G.; Ewald, J.; Chang, L.; Hacariz, O.; Basu, N.; Xia, J. Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat. Protoc. 2022, 17, 1735–1761. [Google Scholar] [CrossRef]
  57. Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017, 45, D353–D361. [Google Scholar] [CrossRef]
  58. Jewison, T.; Su, Y.; Disfany, F.M.; Liang, Y.; Knox, C.; Maciejewski, A.; Poelzer, J.; Huynh, J.; Zhou, Y.; Arndt, D.; et al. SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database. Nucleic Acids Res. 2013, 42, D478–D484. [Google Scholar] [CrossRef]
  59. Xia, J.; Wishart, D.S. MSEA: A web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucleic Acids Res. 2010, 38, W71–W77. [Google Scholar] [CrossRef]
  60. Picart-Armada, S.; Fernández-Albert, F.; Vinaixa, M.; Yanes, O.; Perera-Lluna, A. FELLA: An R package to enrich metabolomics data. BMC Bioinform. 2018, 19, 538. [Google Scholar] [CrossRef]
  61. Jassal, B.; Matthews, L.; Viteri, G.; Gong, C.; Lorente, P.; Fabregat, A.; Sidiropoulos, K.; Cook, J.; Gillespie, M.; Haw, R.; et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2019, 48, D498–D503. [Google Scholar] [CrossRef]
  62. Brunk, E.; Sahoo, S.; Zielinski, D.C.; Altunkaya, A.; Dräger, A.; Mih, N.; Gatto, F.; Nilsson, A.; Preciat Gonzalez, G.A.; Aurich, M.K.; et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 2018, 36, 272–281. [Google Scholar] [CrossRef]
  63. Wang, Z.; Gerstein, M.; Snyder, M. RNA-Seq: A revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10, 57–63. [Google Scholar] [CrossRef]
  64. Fiehn, O.; Robertson, D.; Griffin, J.; Van Der Werf, M.; Nikolau, B.; Morrison, N.; Sumner, L.W.; Goodacre, R.; Hardy, N.W.; Taylor, C.; et al. The metabolomics standards initiative (MSI). Metabolomics 2007, 3, 175–178. [Google Scholar] [CrossRef]
  65. Sumner, L.W.; Amberg, A.; Barrett, D.; Beale, M.H.; Beger, R.; Daykin, C.A.; Fan, T.W.M.; Fiehn, O.; Goodacre, R.; Griffin, J.L.; et al. Proposed minimum reporting standards for chemical analysis. Metabolomics 2007, 3, 211–221. [Google Scholar] [CrossRef] [PubMed]
  66. Sud, M.; Fahy, E.; Cotter, D.; Azam, K.; Vadivelu, I.; Burant, C.; Edison, A.; Fiehn, O.; Higashi, R.; Nair, K.S.; et al. Metabolomics Workbench: An international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res. 2015, 44, D463–D470. [Google Scholar] [CrossRef] [PubMed]
  67. Zhang, Y.; Zhang, H.; Chang, D.; Guo, F.; Pan, H.; Yang, Y. Metabolomics approach by 1H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. Arthritis Res. Ther. 2018, 20, 111. [Google Scholar] [CrossRef]
  68. Zhong, Z.; Huang, Y.; Huang, Q.; Zheng, S.; Huang, Z.; Deng, W.; Li, T. Serum metabolic profiling analysis of gout patients based on UPLC-Q-TOF/MS. Clin. Chim. Acta 2021, 515, 52–60. [Google Scholar] [CrossRef]
  69. Huang, Y.; Xiao, M.; Ou, J.; Lv, Q.; Wei, Q.; Chen, Z.; Wu, J.; Tu, L.; Jiang, Y.; Zhang, X.; et al. Identification of the urine and serum metabolomics signature of gout. Rheumatology 2020, 59, 2960–2969. [Google Scholar] [CrossRef] [PubMed]
  70. Lyu, S.; Rao, Y.; Liu, P.; Yang, S.; Chen, W.; Yang, H.; Ke, S.; OuYang, H.; He, M.; Feng, Y. Metabolomics analysis reveals four biomarkers associated with the gouty arthritis progression in patients with sequential stages. Semin. Arthritis Rheum. 2022, 55, 152022. [Google Scholar] [CrossRef]
  71. Li, Q.; Wei, S.; Wu, D.; Wen, C.; Zhou, J. Urinary Metabolomics Study of Patients with Gout Using Gas Chromatography-Mass Spectrometry. Biomed. Res. Int. 2018, 2018, 3461572. [Google Scholar] [CrossRef] [PubMed]
  72. Shao, T.; Shao, L.; Li, H.; Xie, Z.; He, Z.; Wen, C. Combined Signature of the Fecal Microbiome and Metabolome in Patients with Gout. Front. Microbiol. 2017, 8, 268. [Google Scholar] [CrossRef]
  73. Liu, S.; Wang, Y.; Liu, H.; Xu, T.; Wang, M.-J.; Lu, J.; Guo, Y.; Chen, W.; Ke, M.; Zhou, G.; et al. Serum lipidomics reveals distinct metabolic profiles for asymptomatic hyperuricemic and gout patients. Rheumatology 2021, 61, 2644–2651. [Google Scholar] [CrossRef]
  74. Cui, L.; Liu, J.; Yan, X.; Hu, S. Identification of Metabolite Biomarkers for Gout Using Capillary Ion Chromatography with Mass Spectrometry. Anal. Chem. 2017, 89, 11737–11743. [Google Scholar] [CrossRef] [PubMed]
  75. Qin, N.; Qin, M.; Shi, W.; Kong, L.; Wang, L.; Xu, G.; Guo, Y.; Zhang, J.; Ma, Q. Investigation of pathogenesis of hyperuricemia based on untargeted and targeted metabolomics. Sci. Rep. 2022, 12, 13980. [Google Scholar] [CrossRef] [PubMed]
  76. Suhre, K.; Shin, S.-Y.; Petersen, A.-K.; Mohney, R.P.; Meredith, D.; Wägele, B.; Altmaier, E.; Deloukas, P.; Erdmann, J.; Grundberg, E.; et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011, 477, 54–60. [Google Scholar] [CrossRef] [PubMed]
  77. Döring, A.; Gieger, C.; Mehta, D.; Gohlke, H.; Prokisch, H.; Coassin, S.; Fischer, G.; Henke, K.; Klopp, N.; Kronenberg, F.; et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat. Genet. 2008, 40, 430–436. [Google Scholar] [CrossRef]
  78. Sulem, P.; Gudbjartsson, D.F.; Walters, G.B.; Helgadottir, H.T.; Helgason, A.; Gudjonsson, S.A.; Zanon, C.; Besenbacher, S.; Bjornsdottir, G.; Magnusson, O.T.; et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat. Genet. 2011, 43, 1127–1130. [Google Scholar] [CrossRef]
  79. Vasiliou, V.; Sandoval, M.; Backos, D.S.; Jackson, B.C.; Chen, Y.; Reigan, P.; Lanaspa, M.A.; Johnson, R.J.; Koppaka, V.; Thompson, D.C. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein–protein interactions with HPRT1. Chem.-Biol. Interact. 2013, 202, 22–31. [Google Scholar] [CrossRef]
  80. Charkoftaki, G.; Chen, Y.; Han, M.; Sandoval, M.; Yu, X.; Zhao, H.; Orlicky, D.J.; Thompson, D.C.; Vasiliou, V. Transcriptomic analysis and plasma metabolomics in Aldh16a1 -null mice reveals a potential role of ALDH16A1 in renal function. Chem.-Biol. Interact. 2017, 276, 15–22. [Google Scholar] [CrossRef]
  81. Crane, J.K. Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenicEscherichia coli. Gut Microbes 2013, 4, 388–391. [Google Scholar] [CrossRef]
  82. Hooper, L.V.; Littman, D.R.; Macpherson, A.J. Interactions Between the Microbiota and the Immune System. Science 2012, 336, 1268–1273. [Google Scholar] [CrossRef]
  83. Ichida, K.; Matsuo, H.; Takada, T.; Nakayama, A.; Murakami, K.; Shimizu, T.; Yamanashi, Y.; Kasuga, H.; Nakashima, H.; Nakamura, T.; et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 2012, 3, 764. [Google Scholar] [CrossRef]
  84. Méndez-Salazar, E.O.; Martínez-Nava, G.A. Uric acid extrarenal excretion: The gut microbiome as an evident yet understated factor in gout development. Rheumatol. Int. 2022, 42, 403–412. [Google Scholar] [CrossRef]
  85. Joshi, A.; McCormick, N.; Yokose, C.; Lu, N.; Choi, H. OP0164 A Population-Based, Prospective Metabolomics Study in the UK Biobank Identifies Glycoprotein Acetyls as a Novel Biomarker of Incident Gout. Ann. Rheum. Dis. 2022, 81 (Suppl. S1), 108. [Google Scholar] [CrossRef]
  86. Lu, J.; Dalbeth, N.; Yin, H.; Li, C.; Merriman, T.R.; Wei, W.H. Mouse models for human hyperuricaemia: A critical review. Nat. Rev. Rheumatol. 2019, 15, 413–426. [Google Scholar] [CrossRef] [PubMed]
  87. Lyu, S.; Ding, R.; Liu, P.; Ouyang, H.; Feng, Y.; Rao, Y.; Yang, S. LC-MS Analysis of Serum for the Metabolomic Investigation of the Effects of Pulchinenoside b4 Administration in Monosodium Urate Crystal-Induced Gouty Arthritis Rat Model. Molecules 2019, 24, 3161. [Google Scholar] [CrossRef]
  88. Shan, B.; Chen, T.; Huang, B.; Liu, Y.; Chen, J. Untargeted metabolomics reveal the therapeutic effects of Ermiao wan categorized formulas on rats with hyperuricemia. J. Ethnopharmacol. 2021, 281, 114545. [Google Scholar] [CrossRef] [PubMed]
  89. Wang, L.-M.; Wang, P.; Teka, T.; Zhang, Y.-C.; Yang, W.-Z.; Zhang, Y.; Wang, T.; Liu, L.-X.; Han, L.-F.; Liu, C.-X. 1H NMR and UHPLC/Q-Orbitrap-MS-Based Metabolomics Combined with 16S rRNA Gut Microbiota Analysis Revealed the Potential Regulation Mechanism of Nuciferine in Hyperuricemia Rats. J. Agric. Food Chem. 2020, 68, 14059–14070. [Google Scholar] [CrossRef]
  90. Zhao, L.; Zhao, T.; Yang, X.; Cao, L.; Xu, R.; Liu, J.; Lin, C.; Yu, Y.; Xuan, D.; Zhu, X.; et al. IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype. Rheumatology 2022, 61, 3841–3853. [Google Scholar] [CrossRef] [PubMed]
  91. Tani, T.; Okamoto, K.; Fujiwara, M.; Katayama, A.; Tsuruoka, S. Metabolomics analysis elucidates unique influences on purine/pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury. Mol. Med. 2019, 25, 40. [Google Scholar] [CrossRef]
Gucdd 01 00006 g001
Figure 1. An overview of metabolomics studies in hyperuricemia and gout. Metabolomics studies are often performed using high-resolution mass spectrometry with multiple bioinformatics tools. In human clinical studies, metabolomics studies use saliva, serum, feces, and urine samples. Examples of some differential metabolites are shown with the different biological sources in gout and HU studies. HU is caused by urate overproduction in the liver or decreased excretion in the kidney, and MSU deposition in the joints triggers gout attacks. HU and gout are associated with multiple metabolic co-morbidities.
Figure 1. An overview of metabolomics studies in hyperuricemia and gout. Metabolomics studies are often performed using high-resolution mass spectrometry with multiple bioinformatics tools. In human clinical studies, metabolomics studies use saliva, serum, feces, and urine samples. Examples of some differential metabolites are shown with the different biological sources in gout and HU studies. HU is caused by urate overproduction in the liver or decreased excretion in the kidney, and MSU deposition in the joints triggers gout attacks. HU and gout are associated with multiple metabolic co-morbidities.
Gucdd 01 00006 g001
Gucdd 01 00006 g002
Figure 2. Venn diagram shows the up- and down-regulated metabolite biomarkers in serum of controls, HU, and gout. The orange text box denotes an increase in patients; the blue text box denotes a decrease in patients; and the yellow text box denotes metabolites reported by different articles with inconsistent trends.
Figure 2. Venn diagram shows the up- and down-regulated metabolite biomarkers in serum of controls, HU, and gout. The orange text box denotes an increase in patients; the blue text box denotes a decrease in patients; and the yellow text box denotes metabolites reported by different articles with inconsistent trends.
Gucdd 01 00006 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, R.; Liang, N.; Tao, Y.; Yin, H. Metabolomics in Hyperuricemia and Gout. Gout Urate Cryst. Depos. Dis. 2023, 1, 49-61. https://doi.org/10.3390/gucdd1010006

AMA Style

Li R, Liang N, Tao Y, Yin H. Metabolomics in Hyperuricemia and Gout. Gout, Urate, and Crystal Deposition Disease. 2023; 1(1):49-61. https://doi.org/10.3390/gucdd1010006

Chicago/Turabian Style

Li, Rui, Ningning Liang, Yongzhen Tao, and Huiyong Yin. 2023. "Metabolomics in Hyperuricemia and Gout" Gout, Urate, and Crystal Deposition Disease 1, no. 1: 49-61. https://doi.org/10.3390/gucdd1010006

APA Style

Li, R., Liang, N., Tao, Y., & Yin, H. (2023). Metabolomics in Hyperuricemia and Gout. Gout, Urate, and Crystal Deposition Disease, 1(1), 49-61. https://doi.org/10.3390/gucdd1010006

Article Metrics

Back to TopTop